EMEA-001050-PIP01-10-M04

Key facts

Invented name
Taltz
Active substance
ixekizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0351/2018
PIP number
EMEA-001050-PIP01-10-M04
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of psoriasis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Eli Lilly & Company Limited

Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
1 rating